Login
$ELDN
$2.01 +$0.04 (2.23%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
David-Alexandre C. Gros Also a director
Chief Executive Officer
53 Not stated Not stated $3,216,148
Paul Little
Chief Financial Officer
62 Since 2021
5 years
2021 $1,592,943
Steven Perrin Also a director
President and Chief Scientific Officer
61 Not stated Not stated $1,696,284
Bryan Smith
General Counsel, Corporate Secretary and Chief Compliance Officer
47 Since 2021
5 years
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Average tenure
5.9 years
from year joined
CEO also chairs the board
No
Keith A. Katkin
Director Age On board Committees Other public boards 2025 pay Source
Keith A. Katkin
54 2017
9 years
Nominating and Corporate Governance Committee · Chair
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), Emergent BioSolutions, Inc. (NYSE: EBS) $487,709
David-Alexandre C. Gros
53 2020
6 years
None stated None stated Paid as CEO
Steven Perrin
61 2020
6 years
None stated None stated Not stated
June Lee
60 2020
6 years
Compensation Committee Nominating and Corporate Governance Committee Science and Technology Committee · Chair
None stated $192,253
Allan D. Kirk
64 2023
3 years
Audit Committee Science and Technology Committee
None stated Not stated
John S. McBride
74 2017
9 years
Audit Committee · Chair Compensation Committee
None stated $192,253
Jan Hillson
73 2021
5 years
Nominating and Corporate Governance Committee Science and Technology Committee
None stated $175,213
James Robinson
56 2023
3 years
Audit Committee Compensation Committee · Chair
UroGen Pharma (Nasdaq: URGN), Petauri Health $189,413

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 30, 2026
Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (the BVF Entities)
beneficial owners of more than 5% of our outstanding voting securities
$18,993,948
2024

Acquired shares of Common Stock and 2024 Pre-Funded Warrants in the 2024 Private Placement

Charles-Edouard Gros
the brother of our Chief Executive Officer
$333,331
2024

Blu-G Nevada Par Equity LLC dba BGN Investing 1, whose shares he beneficially owns, acquired 140,646 shares of Common Stock in the 2024 Private Placement

Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (the BVF Entities)
beneficial owners of more than 5% of our outstanding voting securities
$17,995,069
2024

Acquired 2024 Offering Pre-Funded Warrants in the 2024 Underwritten Offering

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support